PURPOSE: The effects of obesity and metabolic dysregulation on cancer survival are inconsistent. To identify high-risk subgroups of obese patients and to examine the joint association of metabolic syndrome (MetSyn) in combination with obesity, we categorized patients with early-stage (I to III) colorectal cancer (CRC) into four metabolic categories defined by the presence of MetSyn and/or obesity and examined associations with survival. METHODS: We studied 2,446 patients diagnosed from 2006 to 2011 at Kaiser Permanente. We assumed MetSyn if patients had three or more of five components present at diagnosis: fasting glucose > 100 mg/dL or diabetes; elevated blood pressure (systolic ≥ 130 mm Hg, diastolic ≥ 85 mm Hg, or antihypertensives); HDL cholesterol < 40 mg/dL (men) or < 50 mg/dL (women); triglycerides ≥ 150 mg/dL or antilipids; and/or highest sex-specific quartile of visceral fat by computed tomography scan (in lieu of waist circumference). We then classified participants according to the presence (or absence) of MetSyn and obesity (BMI < 30 or ≥ 30 kg/m2) and assessed associations with overall and CRC-related survival using Cox proportional hazards models adjusted for demographic, tumor, and treatment factors and muscle mass at diagnosis. RESULTS: Over a median follow-up of 6 years, 601 patients died, 325 as a result of CRC. Mean (SD) age was 64 (11) years. Compared with the reference of nonobese patients without MetSyn (n = 1,225), for overall survival the hazard ratios (HR) and 95% CIs were 1.45 (1.12 to 1.82) for obese patients with MetSyn (n = 480); 1.09 (0.83 to 1.44) for the nonobese with MetSyn (n = 417), and 1.00 (0.80 to 1.26) for obese patients without MetSyn (n = 324). Obesity with MetSyn also predicted CRC-related survival: 1.49 (1.09 to 2.02). The hazard of death increased with the number of MetSyn components present, independent of obesity. CONCLUSION: Patients with early-stage CRC with obesity and MetSyn have worse survival, overall and CRC related.
PURPOSE: The effects of obesity and metabolic dysregulation on cancer survival are inconsistent. To identify high-risk subgroups of obesepatients and to examine the joint association of metabolic syndrome (MetSyn) in combination with obesity, we categorized patients with early-stage (I to III) colorectal cancer (CRC) into four metabolic categories defined by the presence of MetSyn and/or obesity and examined associations with survival. METHODS: We studied 2,446 patients diagnosed from 2006 to 2011 at Kaiser Permanente. We assumed MetSyn if patients had three or more of five components present at diagnosis: fasting glucose > 100 mg/dL or diabetes; elevated blood pressure (systolic ≥ 130 mm Hg, diastolic ≥ 85 mm Hg, or antihypertensives); HDL cholesterol < 40 mg/dL (men) or < 50 mg/dL (women); triglycerides ≥ 150 mg/dL or antilipids; and/or highest sex-specific quartile of visceral fat by computed tomography scan (in lieu of waist circumference). We then classified participants according to the presence (or absence) of MetSyn and obesity (BMI < 30 or ≥ 30 kg/m2) and assessed associations with overall and CRC-related survival using Cox proportional hazards models adjusted for demographic, tumor, and treatment factors and muscle mass at diagnosis. RESULTS: Over a median follow-up of 6 years, 601 patients died, 325 as a result of CRC. Mean (SD) age was 64 (11) years. Compared with the reference of nonobese patients without MetSyn (n = 1,225), for overall survival the hazard ratios (HR) and 95% CIs were 1.45 (1.12 to 1.82) for obesepatients with MetSyn (n = 480); 1.09 (0.83 to 1.44) for the nonobese with MetSyn (n = 417), and 1.00 (0.80 to 1.26) for obesepatients without MetSyn (n = 324). Obesity with MetSyn also predicted CRC-related survival: 1.49 (1.09 to 2.02). The hazard of death increased with the number of MetSyn components present, independent of obesity. CONCLUSION:Patients with early-stage CRC with obesity and MetSyn have worse survival, overall and CRC related.
Authors: Josephina G Kuiper; Amanda I Phipps; Marian L Neuhouser; Rowan T Chlebowski; Cynthia A Thomson; Melinda L Irwin; Dorothy S Lane; Jean Wactawski-Wende; Lifang Hou; Rebecca D Jackson; Ellen Kampman; Polly A Newcomb Journal: Cancer Causes Control Date: 2012-10-02 Impact factor: 2.506
Authors: Laura A Colangelo; Susan M Gapstur; Peter H Gann; Alan R Dyer; Kiang Liu Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-04 Impact factor: 4.254
Authors: Joshua A Bell; Mark Hamer; Séverine Sabia; Archana Singh-Manoux; G David Batty; Mika Kivimaki Journal: J Am Coll Cardiol Date: 2015-01-06 Impact factor: 24.094
Authors: William C Hsu; Maria Rosario G Araneta; Alka M Kanaya; Jane L Chiang; Wilfred Fujimoto Journal: Diabetes Care Date: 2015-01 Impact factor: 19.112
Authors: Jessica J Hopkins; Rebecca Reif; David Bigam; Vickie E Baracos; Dean T Eurich; Michael M Sawyer Journal: World J Surg Date: 2019-10 Impact factor: 3.352
Authors: Kana Wu; Mike Z Zhai; Erin K Weltzien; Elizabeth M Cespedes Feliciano; Jeffrey A Meyerhardt; Edward Giovannucci; Bette J Caan Journal: Cancer Causes Control Date: 2018-11-15 Impact factor: 2.506
Authors: Elizabeth M Cespedes Feliciano; Candyce H Kroenke; Jeffrey A Meyerhardt; Carla M Prado; Patrick T Bradshaw; Marilyn L Kwan; Jingjie Xiao; Stacey Alexeeff; Douglas Corley; Erin Weltzien; Adrienne L Castillo; Bette J Caan Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Elizabeth M Cespedes Feliciano; Valerie S Lee; Carla M Prado; Jeffrey A Meyerhardt; Stacey Alexeeff; Candyce H Kroenke; Jingjie Xiao; Adrienne L Castillo; Bette J Caan Journal: Cancer Date: 2017-09-07 Impact factor: 6.860
Authors: Mingyang Song; Kana Wu; Jeffrey A Meyerhardt; Shuji Ogino; Molin Wang; Charles S Fuchs; Edward L Giovannucci; Andrew T Chan Journal: JAMA Oncol Date: 2018-01-01 Impact factor: 31.777
Authors: Daniel T Dibaba; Suzanne E Judd; Susan C Gilchrist; Mary Cushman; Maria Pisu; Monika Safford; Tomi Akinyemiju Journal: Metabolism Date: 2019-02-23 Impact factor: 8.694